MODERNA, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 142.6 USD | -5.89% |
|
-14.43% | +43.36% |
| May. 31 | Health Care Stocks Climb On Drug News -- Health Care Roundup | DJ |
| May. 31 | Equities Mostly Rise as Fed's Preferred Inflation Measure Meets Street Views | MT |
ETFs positioned on Moderna, Inc.
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.08% | 391 M€ | +7.63% | - | |
| 0.08% | 205 M€ | -.--% | ||
| 0.08% | 14 M€ | +16.19% | - | |
| 0.07% | 0 M€ | 0.00% | - | |
| 0.07% | 571 M€ | +7.61% | - | |
| 0.07% | 375 M€ | +8.36% | ||
| 0.07% | 45 M€ | -.--% | - | |
| 0.07% | 786 M€ | -.--% | ||
| 0.07% | 23 M€ | -.--% | - | |
| 0.07% | 2 M€ | +3.16% | - | |
| 0.07% | 1,166 M€ | +0.26% | - | |
| 0.07% | 607 M€ | +0.05% | - | |
| 0.06% | 206 M€ | -.--% | ||
| 0.06% | 34 M€ | +7.50% | - | |
| 0.06% | 15 M€ | -1.62% | - | |
| 0.06% | 284 M€ | -.--% | ||
| 0.05% | 112 M€ | +4.61% | - | |
| 0.05% | 12 M€ | +15.06% | - | |
| 0.05% | 756 M€ | +0.05% | - | |
| 0.05% | 306 M€ | +5.07% | - | |
| 0.05% | 39 M€ | +5.00% | - | |
| 0.04% | 105 M€ | +2.97% | - | |
| 0.04% | 322 M€ | +13.88% | - | |
| 0.04% | 29 M€ | -.--% | - | |
| 0.04% | 414 M€ | +10.84% | - | |
| 0.04% | 1,006 M€ | -.--% | - | |
| 0.04% | 17 M€ | +2.42% | - | |
| 0.03% | 32 M€ | +0.28% | - |
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
142.6
USD
Average target price
139.9
USD
Spread / Average Target
-1.83%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +43.36% | 54.64B | |
| -5.31% | 39.92B | |
| +37.52% | 38.82B | |
| +14.75% | 26.86B | |
| -12.56% | 26.22B | |
| -22.45% | 18.78B | |
| +25.12% | 12.21B | |
| +0.04% | 12.16B | |
| +26.04% | 11.94B | |
| -11.83% | 10.74B |
- Stock Market
- Equities
- MRNA Stock
- Funds and ETFs Moderna, Inc.
